
Filed by Falcon Capital Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Sharecare, Inc. Commission File No. 333-253113 Date: June 11, 2021





ALL TOGETHER BETTER Proven Track Record







Sharecare is a **health & well-being digital hub** that **unifies all the elements** of individual and community health so everyone can **live better, longer**.

We provide an **interoperable platform** integrating fragmented point solutions and disparate stakeholders to foster a frictionless user-friendly experience that engages people across the **dynamic continuum of their healthcare needs**. We're all together better when:

- we unify the entire ecosystem health plans, employers, providers, life sciences – into one connected system
- we turn point solutions into an integrated platform in the palm of a person's hand
- we turn individual progress into community transformation

All Together Better

ALL TOGETHER BETTER Diverse Team of Innovators, Operators, and Unifiers








ALL TOGETHER BETTER

Delivering Accelerated Growth with Significant Operating Leverage



6




Note: includes doc.al acquisition; adjusted EBITDA reflects removal of non-cash operating expenses (stock option compensation expense), severance and acquisition-related costs; 2021 forecast includes \$3.9M of IPO-related operating expenses




High-growth, recurring revenue driving 20% sustainable YoY growth


@ sharecare















ENTERPRISE SOLUTIONS Land and Expand: Comprehensive Offering to Improve Health





Health Plan Client: Accelerated growth for diabetes prevention program from 500 members/month to "3K members/month (in past 6 months) with an eligible population of "400K members.



ENTERPRISE SOLUTIONS



Established Strategy to Drive Revenue Growth Utilizing an omni-channel approach to activating **7M+ eligible lives** in digital therapeutics across currently contracted client base

Expand footprint	 New logos Additional Blues and other health plans Executing on prospective pipeline representing ~9,500 new employers
New digital therapeutics product offerings	 Increase digital therapeutics programs offerings for 2021 Hypertension, asthma/COPD, sleep, EAP, mental health, second opinion, advocacy/concierge Immediate revenue to Sharecare based on existing contracts Ability to activate anytime during calendar year
Activate eligible lives within clients	 Investing in advanced sales and marketing tactics Targeted digital modeling and marketing to expand eligible activations







Improving Efficiency and Patient Care




17



Pricing structure differs by product: Gainshare, SaaS platform fee, per record request

Client base: 6,000 hospitals & physician practices, 95+ health plans and audit clients

Services are in **strategic and financial alignment with providers** offering significant benefits and revenue upside





* estimated



Comprehensive Solutions Addressing Providers' Needs






Building upon core provider service to offer incremental services with existing contracts representing a \$1B opportunity




Driving Significant Near-Term Revenue Growth and Margin Expansion



Expand product portfolio	 Deploy value-based care and payment integrity across 6,000 clients Integrate denial management services & remote patient monitoring Sharecare-enabled clinician to close gaps-in-care
Expand customer	 Continue momentum with organic growth with new health system and payor clients Opportunity to expand top 25 currently contracted clients to additional 4,000+ sites
footprint	 Leveraging channel partnerships to increase penetration into the MSK space and increase sales velocity
	 Leverage deep relationships in employer and health plan space to cross-sell payment integrity solutions








* estimated; 2020 revenue figure excludes \$3M in sales from discontinued operations



Driving Growth with Core Life Sciences Clients and New Initiatives




Retention and growth of existing life sciences clients	 Expand beyond our current life sciences brand campaigns Contract renewals with significant increases in commitments 80%+ retention rate
Focus on integrated marketing solutions	 Advance targeting through real-time health profiling engine Leverage expert content, high engagement experiences Continue to roll out new innovative, interactive products
Enhanced performance & scale	 Advanced analytics, predictive modeling and insights Grow SEO traffic via web enhancements Continue to grow members/registrations
Visual health & paid apps	 Expand YOU platform of <i>medical animations and paid app sales</i> Launch new mental health and well-being paid app, Unwinding Grow streaming service and clinical customers of Sharecare Windows content (Amazon Prime streams 3.8 years of content daily)









пů

....

#

A8 ~

Recommended for you See All

Take control of your anxiety with Unwinding Anxiety

241

ft. Ψ 0 0 Θ



DATA & INNOVATION The Future of UI is No UI





- We leverage every component of the phone •
- . People live on their phones, consume and collect data via pictures, videos, voice
- ٠ We have built neural nets under the form of smart selfies, smart videos and smart pictures
- For a frictionless experience that augments engagement
- We are adding new dry bio-markers for progression and regression . of symptoms







SDOH



Face

Smart selfie

Al for medication

Al for mood

Al for

food

Wallet for rewards

Environmental Chatbot health

Telehealth

Genome browser

Voice





differentiated financial per Key Financial	
Revenue visibility	Recurring revenue driven by multi-year contracts
Scale	 Diversified customer base drives opportunity to upsell to existing clients and cross-sell across our divisions Expanded customer base with major enterprise client wins – Centene, Humana, Delta – with significant pipeline of potential clients
Growth	 Platform positioned to capture significant digital health opportunity Launched new digital therapeutics product line with \$1B opportunity from existing clients Introduced health security and vaccine adherence solutions
유규 ⁽⁾ ⁽⁾ ⁽⁾ ⁽⁾ ⁽⁾ ⁽⁾	 Adjusted EBITDA positive with continued operating leverage Medium-term opportunity to drive gross margin and adjusted EBITDA margins to 55% and 25%, respectively
	29



Delivering Accelerated Growth

Achieve scale profitability through significant operating leverage

Projected Financial Summary

(\$, in millions)

	2020A	2021E	2022E	2023E	20-23E CAGR	Medium term
Revenue	\$329	\$408	\$533	\$653	26%	\$1,000
Gross profit	169	208	286	364	29%	550
Gross margin	51%	51%	54%	56%	-	55%
Adjusted EBITDA	\$32	\$31	\$61	\$101	46%	\$250
Adjusted EBITDA margin	9%	8%	11%	15%	-	25%


NOTE: Adjusted EBITDA reflects removal of non-cash operating expenses (stock option compensation expense and warrant value tied to client contracts), severance and acquisition-related costs; projections include doc.ai acquisition; 2021 forecast includes \$3.9M of IPO-related operating expenses.



97% of 2021 is Contracted as of Today



Focusing the growth story: Base case provides substantial growth with further opportunity for upside





Q1

- 1. Revenue of \$89.6M compared to \$81.9M, an increase of 9%
- 2. Adjusted EBITDA of \$6.5M, representing an increase of 96%

Q2

- 1. Q2 revenue guidance is \$96.5M \$98.5M (~23%+ growth over prior year period)
- Revenue growth over prior quarter (Q1 2021) is projected to be ~\$7M - \$9M (or ~8%+)
- 3. Q2 Adj of EBITDA \$6.5M is in line with expectations

H1 Highlights

- Added new employer, government, provider, and life sciences customers
- 2. Expanded into the Medicaid/Medicare Advantage market
- Accelerated adoption of various digital therapeutics marketplace offerings
- 4. Successfully launched new health security products into the market
- Secured \$50M investment from second largest health plan in U.S. to co-develop next generation multi-payor advocacy solution as an extension to the Sharecare digital platform





Built for Scale and Accelerated Revenue Growth
















(\$ in millions)

Sources

TRANSACTION OVERVIEW Pro Forma Capitalization and Ownership



Key Deal Considerations:

- Up to \$770M of cash from Falcon and PIPE investors
- + \$401M of PF cash at closing to drive additional investments and M&A
- + \$275M of secondary sale relative to \$450M of total invested capital
- Represents less than 7% of total PF equity value
- · Pro-Rata selling of secondary shares by senior leadership in the transaction
- · Post-money EV/2021E revenue of 9.

Estimated

	DE transaction
	(\$ In millions)
Transaction Sources & Uses ¹	
0.5x	

Cash from Falcon Capital Acquisition Corp.	\$345
Cash from PIPE	425
Strategic preferred investment ²	25
Total Sources	\$795

Uses	
Cash to existing shareholders	\$275
Cash to balance sheet	401
Cash to repay existing debt	65
Estimated transaction expenses	54
Total uses	\$795

Pro Forma Ownership:

- Sharecare investors and insiders to own 80%
- · Proper alignment with senior management and employees for long-term value creation Senior management/employee ownership (incl. stock options): 22%
 - Senior leadership locked up for 12 months (subject to performance triggers)
- SPAC IPO/PIPE investors will own 20%

Post-Money Valuation at Close

PF transaction	
Sharecare pre-money equity value	\$ 3,768
(+) SPAC IPO shares	345
(+) PIPE & strategic preferred investment	450
(+) Founder shares ¹	56
(-) Secondary sale	(275)
Total equity value	\$ 4,343
(+) Debt at close	0
(-) Cash at close	(401)
PF Enterprise value	\$ 3,942
PF EV / 21E revenue	9.5 x

¹ Gives effect to surrender 15% of Founder shares held by Sponsor and a transfer of 5% to a Sharecare charity. 75% of the remaining 80% to convert to Class A shares upon closing of the merger. Balance subject to stock price-performance based earnouts. Assumes no earnout or warrant exercise at closing. Assumes no redemptions. 4525-50M of convertible preferred stock, 5-year mandatory redemption, terms to be finalized per definitive documentation. Note: Includes the \$175M acquisition of doc.ai, with consideration in the form of \$146M in stock and \$29M in cash. 38



TRANSACTION OVERVIEW Attractive Entry Point for Investors



